Coronavirus Infection Clinical Trial
Official title:
Fourth Dose of Pfizer mRNA COVID-19 Vaccine in Residents of Long-Term Care Facilities
This study is a multi-centre, blinded, randomized controlled trial. LTCF residents ≥ 65 years who have received three doses of mRNA vaccine will be randomized to vaccination with a fourth dose of Pfizer-BioNtech mRNA- COVID-19 vaccine or to vaccination with a control (Prevnar-13 vaccine).
The primary objective of this study is to test whether vaccinating LTCF residents ≥65 years with a fourth dose of Pfizer-BioNtech mRNA- COVID-19 vaccine as compared to control (PCV13) leads to an increase in detectable neutralizing antibodies. Participants will be randomized to receive either the Pfizer COVID-19 vaccine or the Pnemoccocal Prevnar-13 vaccine at baseline after bloodwork is drawn. Another blood sample will be taken 28 days later. After completion of the study, participants in the control group (pneumococcal Prevnar-13 vaccine) will be given a fourth dose of mRNA COVID-19 vaccine and will have their blood drawn 28 days post-vaccination. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04369456 -
Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients
|
N/A | |
| Completed |
NCT04527471 -
Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
|
Phase 2 | |
| Recruiting |
NCT04410510 -
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT04383899 -
Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019
|
||
| Completed |
NCT04542915 -
COVID-19-Related Health and Practices Among Dental Hygienists
|
||
| Not yet recruiting |
NCT04400019 -
Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)
|
Phase 2/Phase 3 | |
| Suspended |
NCT04385771 -
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
| Completed |
NCT04532632 -
Taste and Smell Impairment in Critically Ill COVID-19 Patients
|
||
| Terminated |
NCT04954014 -
Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
|
Phase 2 | |
| Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
| Completed |
NCT04413435 -
Clinical Characteristics of Critically Ill Patients With COVID-19
|
||
| Terminated |
NCT05593770 -
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
|
Phase 2/Phase 3 | |
| Completed |
NCT04510493 -
Canakinumab in Patients With COVID-19 and Type 2 Diabetes
|
Phase 3 | |
| Active, not recruiting |
NCT04587219 -
The Study of "Gam-COVID-Vac" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older
|
Phase 2 | |
| Withdrawn |
NCT05430958 -
Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04596579 -
SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida
|
||
| Completed |
NCT04405934 -
COG-UK Project Hospital-Onset COVID-19 Infections Study
|
N/A | |
| Enrolling by invitation |
NCT04484025 -
SPI-1005 Treatment in Moderate COVID-19 Patients
|
Phase 2 | |
| Terminated |
NCT04442230 -
NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
|
Phase 2 | |
| Terminated |
NCT04642638 -
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
|
Phase 2/Phase 3 |